# Normal zinc, low thymulin activity — BioLink Peptides

> BioLink Peptides explores a disagreement between plasma zinc and thymulin activity, then follows zinc-binding proteins, old mice and human immune cells.

**Thymulin · Zinc · Immune cells**

A human study reported [reduced thymulin activity despite normal plasma zinc](https://pubmed.ncbi.nlm.nih.gov/3262625/). That disagreement has me wondering where the zinc is held.

## The human zinc experiment

In [the 1988 human zinc-deficiency study](https://pubmed.ncbi.nlm.nih.gov/3262625/), dietary-restriction volunteers and adults with and without sickle-cell anaemia supplied an awkward pair of findings: normal plasma zinc and reduced serum thymulin activity. Zinc repletion corrected that activity, both when given to participants and when added to samples in the laboratory. Reversible changes in T-cell subsets and IL-2 activity accompanied the findings.

I’d happily devote an afternoon to this awkward pairing. There was zinc in the plasma, yet the biological activity of a zinc-dependent hormone was diminished. The experiment gives BioLink its subject: the connection between a metal’s availability, a peptide’s activity and immune-cell behaviour. For me, the middle of that relationship is the absorbing part: a concentration measurement can leave a functional question open.

## Thymulin and its metal partner

[Thymulin is a zinc-dependent thymic hormone](https://pubmed.ncbi.nlm.nih.gov/2657247/) associated with T-lymphocyte maturation and the functions of T-cell subsets. Its metal partner matters to its biological activity. That makes the human zinc experiment a particularly satisfying place to begin: the chemistry has consequences that an assay can pick up.

My first question concerned the amount of thymulin present. After this experiment, its ability to function became the more compelling question. [Zinc and thymulin](/zinc-and-thymulin) takes that question back to the hormone itself.

## The other proteins in the sample

The story becomes less tidy when zinc has other partners. In [a study of cervical-carcinoma patients](https://pubmed.ncbi.nlm.nih.gov/9888464/), reduced active thymulin again appeared alongside normal plasma zinc; the authors attributed the finding to competition for zinc from elevated alpha-2-macroglobulin, a zinc-binding protein. An [aging-mouse paper on metallothioneins](https://pubmed.ncbi.nlm.nih.gov/15679929/) proposed another way zinc could be held away from thymulin.

These are different populations and different proposed mechanisms. I wouldn’t collapse them into a universal explanation for a low result. Their attraction is more specific: they make the location and availability of zinc interesting. [The zinc-carrier essay](/zinc-carriers) follows that competition.

## Two further stops

[Old mice and the thymus](/old-mice) compares an oral-zinc experiment with a thymus-organ-culture experiment. The distinction between recovery of thymic function and partial recovery of peripheral immune function deserves some room.

[Human cells in culture](/human-cells) moves to marrow precursors and lymphocytes from particular patient groups. Those experiments are engrossing on their own terms: cells acquire markers, subsets change, and the result remains attached to the cells that were actually examined. I’m much more curious about those changes than about a general claim to ‘boost’ immunity.

---

My curiosity about thymulin and zinc lives at BioLink Peptides, a home for published research that offers no medical advice or commercial service.